Bintai Kinden Corporation Bhd (BKCB) and Institut Jantung Negara Sdn Bhd (IJN) have forged strategic partnerships to explore possible collaborations in the commercial development of the Covid-19 vaccine in Malaysia.
In a filing to Bursa Malaysia today, BKCB said both parties have signed a Memorandum of Understanding (MoU) for 3 years. Based on the agreement, BKCB will be responsible for introducing the Covid-19 vaccine in Malaysia.
In addition, all clinical trials required by the Ministry of Health will be conducted and led by IJNSB, which will also be the Clinical Research Organization and one of the study sites for BKCB.
Meanwhile, BKCB revealed that it have partnered with US-based Generex Biotechnology Corporation to promote the commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in Malaysia.
For all intents and purposes, the vaccine developed is known as a ‘complete vaccine’ that has the potential to induce T-Cell immune responses and antibodies that can provide protective immunity with long-term immunological memory of SARS-CoV-2 in a very specific way to ensure safety.
Once Generex has received full US Food and Drug Administration approval for the vaccine and provided complete documentation to the BKCB, they will begin the registration process with the National Pharmaceutical Supervisory Agency for the vaccine.
Meanwhile, the MoU will not affect BKCB's issued and paid-up share capital but the estimated gross development value proposed is expected to contribute positively to the group's future income.
